Asma Charkhabi - MSc of Microbiology Biology, Noor Danesh Institute, Meymeh, Esfahan, Iran
Kamran Ghaedi - PhD, Department of Biology, Faculty of Sciences, University of Isfahan, Iran
Bagher Yakhchali - PhD, National Institute of Genetic Engineering and Biotechnology (NIGEB), Tehran, Iran
Marzieh Alamatsaz - MSc of Cellular and Molecular Biology, Noor Danesh Institute, Meymeh, Isfahan, Iran

Nowadays a variety of medicines are used to diagnose, treat, improve or prevent cancers. Cancers are a group of illnesses that are originated from uncontrolled proliferation of cells which lead to a tumor. For this reason, Food and Drug Administration (FDA) has focused a special attention on therapeutic enzymes to treat cancer because enzymes are specifically act, and they are highly capable to be used for treatments. Among the enzymes, lipase (triacylglycerol EC 3.1.1.3) is ranked as the third most widely used enzyme. Furthermore, due to its high stability in particular situations, is an appropriate molecule in the pharmaceutical industry for cancer treatment. According to the studies and reviews that were published by a number of researchers from 2006 to 2016: lipase, amylase, protease which easily digest fats, proteins and starch in the digestive tract are very effective in treating of gastrointestinal cancer. Nowadays, in USA and Sweden, using genetic engineering, recombinant enzyme is produced for treatment of skin, breast and lung cancers. Taken together, the high use and low cost of lipase made it an ideal approach for cancer therapy. In the present report we intend to review the literatures based on application of lipase as a therapeutic approach against cancer progress.

Therapeutic enzyme, Lipase, Cancer